Table 2.
Summary of the primary drug therapy interventions examined using the simulation
| Intervention | Therapy |
|---|---|
| AL extension | AL (4-d course) |
| AL (5-d course) | |
| AL (3-d course on days 0, 1 and 2) followed up with a second course on days 7, 8 and 9; labeled ‘AL789’ | |
| AL replacement | ASAQ |
| DHA–PPQ | |
| MFTs | ASAQ (75%) + DHA–PPQ (25%) |
| ASAQ (50%) + DHA–PPQ (50%) | |
| ASAQ (25%) + DHA–PPQ (75%) | |
| AL (75%) + ASAQ (25%) | |
| AL (50%) + ASAQ (50%) | |
| AL (25%) + ASAQ (75%) | |
| AL (75%) + DHA–PPQ (25%) | |
| AL (50%) + DHA–PPQ (50%) | |
| AL (25%) + DHA–PPQ (75%) | |
| Sequential courses of 3-d ACT | AL on days 0, 1 and 2, followed by ASAQ on days 3, 4 and 5; labeled ‘AL, then ASAQ345’ |
| AL on days 0, 1 and 2, followed by DHA–PPQ on days 3, 4 and 5 | |
| ASAQ on days 0, 1 and 2, followed by AL on days 3, 4 and 5 | |
| DHA–PPQ on days 0, 1 and 2, followed by AL on days 3, 4 and 5 | |
| AL on days 0, 1 and 2, followed by ASAQ on days 7, 8 and 9; labeled ‘AL, then ASAQ789’ | |
| AL on days 0, 1 and 2, followed by DHA–PPQ on days 7, 8 and 9 | |
| ASAQ on days 0, 1 and 2, followed by AL on days 7, 8 and 9 | |
| DHA–PPQ on days 0, 1 and 2, followed by AL on days 7, 8 and 9 | |
| Switch to DHA–PPQ, followed by switch to MFT | DHA–PPQ (3 years), then AL (50%) + ASAQ (50%) |
| DHA–PPQ (3 years), then 5-d course of AL (50%) + ASAQ (50%) | |
| Triple ACT (TACT) | ALAQ |
| ASMQ–PPQ |